The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 2
Which of the following is NOT a current or future innovative solution to the common challenges facing CAR T-cell therapy?
A
B
C
D
Video series
During the EHA 2023 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint satellite session on the ins and outs of CAR T cells in the real world.
Here, we share the presentation by Michael Hudecek, University Hospital Würzburg, Würzburg, DE, discussing answers to common challenges in CAR T-cell therapy.
In this presentation, Hudecek identifies limitations in patient access and inefficient manufacturing protocols as the main challenges currently restricting the scalability of CAR T-cell therapies (Figure 1), before highlighting some possible innovative answers (Figure 2).
Figure 1. The effect of limited patient access on CAR T-cell therapy for patients with DLBCL in Italy*
CAR, chimeric antigen receptor; DLBCL, diffuse large B-cell lymphoma; R/R, relapsed/refractory;
2L, second line.
*Adapted from Jommi, et al.1
Figure 2. The impact of centralized CAR T-cell manufacturing on wait times for CAR T-cell infusion*
CAR, chimeric antigen receptor; PoC, point of care.
*Created with BioRender.com
Watch or download the presentation to learn more about the common challenges and solutions facing CAR T-cell therapy today, including:
This activity was supported through an educational grant from Bristol Myers Squibb.
References